Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 2Depression 2Anxiety Disorders 2Skin Neoplasms 1Polycystic Ovary Syndrome 1Keratosis, Actinic 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasms × Niacin × Clear all
NCT00302744 2025-03-13

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Phase 1/2 Completed
12 enrolled

Anxiety Disorders, Depression, Neoplasms

NCT00957359 2020-10-20

Psilocybin Cancer Anxiety Study

NYU Langone Health

Phase EARLY_PHASE1 Completed
29 enrolled 59 charts

Anxiety Disorders, Depression, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡